Journal profile · Urology & Nephrology
Urologic Oncology Seminars and Original Investigations
ISSN 1078-1439 · eISSN 1873-2496 · Elsevier Inc. · UNITED STATES · Bimonthly · Founded 1995
Urologic Oncology Seminars and Original Investigations: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 2.5; hybrid open access; APC about USD 3,440; median 112 days to acceptance (116 articles, last 24 months); community-reported acceptance: fairly easy; 613 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Urologic Oncology Seminars and Original Investigations is published by Elsevier Inc. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Bladder and Urothelial Cancer Treatments, Prostate Cancer Diagnosis and Treatment and Prostate Cancer Treatment and Research, together about 44.7% of its articles. Its main subfields are Surgery and Pulmonary and Respiratory Medicine. (generated from OpenAlex topic counts and CAS ranking data)
Official Journal of the Society of Urologic OncologyUrologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.
From the journal's Aims & Scope
Research area (LetPub): Urology & Nephrology
Editor-in-chief Jodi MaranchiePublisher website
Editorial board by country: none in mainland China; most named United States 68, Germany 7, Canada 4, United Kingdom 2, Japan 2 (85 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Bladder and Urothelial Cancer TreatmentsMedicine18.7%
- Prostate Cancer Diagnosis and TreatmentMedicine13.4%
- Prostate Cancer Treatment and ResearchMedicine12.6%
- Renal cell carcinoma treatmentMedicine9.2%
- Urinary and Genital Oncology StudiesMedicine7.6%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.1%
- Human auditory perception and evaluationEngineering2.9%
- Multiple and Secondary Primary CancersMedicine2.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
| Minor | Urology & Nephrology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
| Minor | Urology & Nephrology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Urology & Nephrology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.5LetPub ·
- Impact factor (publisher)
- 2.8Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- CiteScore (publisher)
- 4.6Publisher website ·
- SJR 2026-06
- 1LetPub ·
- SNIP 2026-06
- 0.88LetPub ·
- h-index
- 62LetPub ·
- h-index
- 108OpenAlex ·
- i10-index
- 3,039OpenAlex ·
- 2-year mean citedness
- 1.47OpenAlex ·
- Self-citation rate
- 7.1%LetPub ·
- Share of gold OA articles
- 20.05%LetPub ·
Volume
- Articles per year
- 295LetPub ·
Articles by year OpenAlex count · 7,588 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 272 | 88 | 69 |
| 2025 | 613 | 109 | 692 |
| 2024 | 581 | 115 | 1,394 |
| 2023 | 256 | 61 | 1,614 |
| 2022 | 287 | 70 | 2,520 |
| 2021 | 360 | 85 | 4,337 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
112 daysMedian, submission to acceptance · P25–P75 78 days – 154 days
- Acceptance to online
- median 26 days (110 articles)
- Submission to online
- median 142 days
- Sample
- 116 articles with submission and acceptance dates (719 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 13 daysPublisher website ·
- First decision after review
- 60 daysPublisher website ·
- Submission to acceptance
- 115 daysPublisher website ·
- Acceptance to publication
- 29 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,440 / EUR 3,220 / GBP 2,750 / JPY 426,660 | — | — | |
| Publisher website | USD 3,580 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Templates
- LaTeX and Word
- Highlights
- Required
- Graphical abstract
- Optional
Article types accepted7
- case reportUROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS supports basic and clinical research subjects. Original articles which address any aspect of urologic on…Length not stated
- case reportsCase reports are currently not being accepted.Length not stated
- original articleUROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS supports basic and clinical research subjects. Original articles which address any aspect of urologic on…Length not stated
- original articlesOriginal articles which address any aspect of urologic oncology are invited.Length not stated
- review articleUROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS supports basic and clinical research subjects. Original articles which address any aspect of urologic on…Length not stated
- review articlesReview articles will also be considered.Length not stated
- surveyUROLOGIC ONCOLOGY: SEMINARS AND ORIGINAL INVESTIGATIONS supports basic and clinical research subjects. Original articles which address any aspect of urologic on…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1995
- ISSN
- 1078-1439
- Electronic ISSN
- 1873-2496
- Society / sponsor
- Society of Urologic Oncology
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Urologic Oncology Seminars and Original Investigations
What CAS zone is Urologic Oncology Seminars and Original Investigations in?
In the 2025 upgraded edition of the CAS Journal Ranking, Urologic Oncology Seminars and Original Investigations is in Zone 3 of Medicine, and in Zone 4 of the minor category Oncology / Urology & Nephrology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Urologic Oncology Seminars and Original Investigations?
The latest impact factor listed by LetPub is 2.5; CiteScore 4.6, h-index 108.
How long does peer review take at Urologic Oncology Seminars and Original Investigations?
Based on the dates recorded on 116 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 112 days (interquartile range 78–154 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Urologic Oncology Seminars and Original Investigations?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Templates: LaTeX and Word; Highlights: Required; Graphical abstract: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Urologic Oncology Seminars and Original Investigations based?
Of the 85 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (68), Germany (7) and Canada (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Urologic Oncology Seminars and Original Investigations?
According to LetPub and DOAJ records, Urologic Oncology Seminars and Original Investigations is indexed in SCIE and Scopus.
Is Urologic Oncology Seminars and Original Investigations open access, and what is the APC?
Urologic Oncology Seminars and Original Investigations is a hybrid journal. For open-access publication: APC about USD 3,440.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .